RE:RE:RE:RE:RE:RE:RE:RE:Stock PriceAlamir1111, actually the burn rate for past 12 months was about $400,000/month not $1 million/month. Roger even mentioned this in his presentation today. And I thought it very wise of him to contrast the less than $5 million/year that Theralase spends compared to $500 million/year of the competition. And Theralase exhibits superior results. So probably only need $3 or $4 million to finish off this bladder cancer trial.
Once the pre-clinical work is complete for GBM and NSCLC let's say 2 or 3 patients each in Ph1. IV administration of Ruvidar plus radiation treatment should be a much less expensive process than our current bladder cancer treatment process.
Alamir1111 wrote: Last year burn rate was bit over 1miilin nbsp; a month.expected to finnish trial end 2026.Thats 30 months away yes min. 30 mill$ .Iguess the rest of planned trials might need extra cash